APA (7th ed.) Citation

K, K., K, H., C, K., K, I., A, W., T, W., . . . N, H. (2026). A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma. Journal of gastroenterology, 61(5), 536. https://doi.org/10.1007/s00535-026-02366-9

Chicago Style (17th ed.) Citation

K, Kumagai, et al. "A Phase I/II Clinical Trial of Neoadjuvant Docetaxel/oxaliplatin/S‑1 (DOS) Combination Therapy for Gastroesophageal Junction Adenocarcinoma." Journal of Gastroenterology 61, no. 5 (2026): 536. https://doi.org/10.1007/s00535-026-02366-9.

MLA (9th ed.) Citation

K, Kumagai, et al. "A Phase I/II Clinical Trial of Neoadjuvant Docetaxel/oxaliplatin/S‑1 (DOS) Combination Therapy for Gastroesophageal Junction Adenocarcinoma." Journal of Gastroenterology, vol. 61, no. 5, 2026, p. 536, https://doi.org/10.1007/s00535-026-02366-9.